Background: Thyroid stunning was defined as transient reduction of thyroid tissue uptake 131I (RAI-131) ablative dose after a diagnostic 131I dose that decreases the final absorbed dose in ablative therapy.Aim of the study: after following the proper precautions compare the response to the ablative dose given to patients with differentiated thyroid cancer with or without diagnostic radioactive iodine 131(RAI-131). Patients and methods:One hundred patients with differentiated thyroid cancer were included and divided into two groups: Group I, ablative dose of RAI-131according to their risk stratification without diagnostic dose and Group II, patients performing diagnostic whole body scan [5mCi] followed by ablative dose. Results:The current study have showed no significant associations between overall response in both groups and the different studied parameters except for the mean ablative dose of P<0.001 and r=0.7, P<0.001 in group I and group II respectively]. Correlation matrix was used in all patients revealed that overall response was highly correlated with risk stratification; cervical nodal status and RAI-131 ablative dose [P values <0.01; <0.01 and <0.01 respectively], while regression proved that the only predictor for response is the mean RAI-131 ablative dose. Conclusion:Following the proper precautions prevent stunning appearance after the diagnostic dose success rate to ablation will not be affected.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.